The Accidental Discovery: How Bacteria Fight Viruses

In a laboratory at the University of California, Berkeley, in the early 2000s, a young biochemist named Jennifer Doudna was studying how bacteria fight viruses. She had no idea that her curiosity about microbial immune systems would eventually lead to a technology capable of rewriting the code of life itself. Her journey, and the larger story of CRISPR, began not with a grand plan to edit human genes, but with a bizarre pattern observed in the DNA of microorganisms—a pattern so strange and repetitive that it was initially dismissed as genomic junk. This is the story of an accidental discovery, a detective hunt across continents and microbial species, where the puzzle of a bacterial immune system laid the foundation for a tool that would later rewrite human destiny. It is a testament to the fact that the most transformative technologies often emerge not from targeted invention, but from the patient, curious exploration of nature’s hidden logic.

The story starts, as many great scientific tales do, with a “why?”—a persistent anomaly that wouldn’t let go. In the late 1980s, microbiologists sequencing the genomes of various bacteria began noticing something peculiar. Interspersed within the long, familiar strings of A, T, C, and G were short, identical sequences that repeated over and over again, like a bizarre stutter in the genetic code. These were not the elegant genes that coded for proteins. They were short palindromic sequences—reads that were the same forwards and backwards, much like the word “level”—and between them lay unique, non-repetitive “spacer” DNA. The entire pattern was known as Clustered Regularly Interspaced Short Palindromic Repeats, or CRISPR for short. For over a decade, this genomic oddity was largely ignored, cataloged as a curious but probably meaningless feature of certain bacterial and archaeal genomes, a bit of molecular noise with no clear function.

The first key to unlocking the mystery came from an unlikely source: yogurt. In 1992, a team at a Danish biotechnology company, Danisco, was studying *Streptococcus thermophilus*, a bacterium essential to yogurt and cheese production, constantly threatened by viruses called bacteriophages. They noticed that different strains of the same bacterium had different spacer sequences between their CRISPR repeats. To the lead scientist, Rodolphe Barrangou, this variation was not random noise; it was a record. It was as if the bacterium was keeping a logbook of its past viral infections, using the foreign DNA snippets from invaders as a memory. When a new virus attacked, the bacterium could compare the invader’s DNA to its stored logbook. If there was a match, it knew it was under threat and could launch a defense. This was the “adaptive” part of the immune system—a memory of past infections, something previously thought to exist only in complex animals. Barrangou’s team proved it in a landmark 2007 experiment: they deleted a specific spacer sequence corresponding to a particular virus from a CRISPR cluster. Without that “memory,” the bacterium became vulnerable. When they reintroduced the spacer, resistance returned. CRISPR was a bacterial immune system, a sophisticated, programmable defense mechanism that had been evolving for billions of years.

While Barrangou was proving CRISPR’s function in the food industry, a parallel detective story was unfolding in the world of basic science, driven by pure curiosity about these strange DNA sequences. The protagonist was Francisco Mojica, a microbiologist at the University of Alicante in Spain. In the early 1990s, while studying halophilic (salt-loving) archaea from the salt flats of Santa Pola, Mojica’s team encountered these repeating sequences. Intrigued by their perfect regularity—a feature almost never seen in random DNA—he dedicated years to studying them across dozens of microbial species. He coined the term CRISPR in 2002 and, crucially, noticed that the mysterious “spacer” DNA often matched sequences from known viruses and plasmids. This was the “aha!” moment: the spacers were not random; they were fragments of invader DNA, a historical archive. Mojica’s work established the fundamental principle, but he, like many others, was so focused on the natural biological system that he did not immediately envision its potential as a human-made tool. The bridge from natural immune system to universal genetic engineering tool required a different kind of mind—one trained in biochemistry and RNA interference, and open to the idea of repurposing a natural machine.

That mind belonged to Jennifer Doudna. By the mid-2000s, Doudna was a renowned expert on RNA, the single-stranded cousin of DNA that plays a central role in gene expression. She was particularly interested in a related bacterial defense system called RNA interference (RNAi), which uses small RNA molecules to silence genes. When she first learned about CRISPR from a colleague, she was immediately captivated by the puzzle: how did these CRISPR RNA sequences, derived from viral DNA, direct a bacterial defense? Her intuition, honed by years of studying RNA-guided processes, was that the answer involved a RNA molecule guiding a protein to cut DNA. The question was: what was the protein?

The answer arrived via an unexpected phone call and a fortuitous collaboration. In 2005, a French scientist named Emmanuelle Charpentier, then at the University of Vienna, contacted Doudna. Charpentier was a specialist in bacterial pathogenesis, studying *Streptococcus pyogenes*, the bacterium responsible for strep throat and scarlet fever. She was investigating the CRISPR system in this pathogen, not for its basic biology, but because she suspected it might be involved in the bacterium’s ability to cause disease. Her lab had identified a gene near the CRISPR region, *cas9* (CRISPR-associated protein 9), which they believed was the key nuclease—the molecular scissors. But they were stuck. Doudna had the RNA expertise; Charpentier had the protein. They decided to combine forces.

What followed was a masterclass in scientific collaboration, conducted largely via transatlantic phone calls and email, with Doudna’s postdoctoral fellow Martin Jinek traveling to Charpentier’s lab in Vienna. Their goal was simple in concept, monumental in execution: to reconstruct the bacterial immune system in a test tube. They needed to synthesize the CRISPR RNA (which they called a “guide RNA” or gRNA), purify the Cas9 protein, and see if the two together could find and cut a specific piece of DNA. The experiment was a high-wire act of biochemistry. If it worked, they would prove the mechanism. If it failed, they would have to start over.

In the spring of 2012, it worked. The test tube contained the guide RNA, the Cas9 protein, and a target DNA molecule with a sequence matching the guide. Under the microscope, they saw the DNA had been sliced cleanly at the precise location dictated by the RNA. It was a programmable DNA-cutting machine. But the true, earth-shattering realization came next. Doudna and Charpentier looked at each other and asked: if this system can be programmed with a guide RNA to cut any DNA sequence we want, could we use it to edit any gene, in any organism? The answer, they soon understood, was yes. The bacterial immune system, honed by evolution to protect prokaryotes from viruses, could be stripped down to its essential components—a single protein (Cas9) and a short, synthetic guide RNA—and deployed as a universal genetic scalpel. They had not invented a new tool; they had discovered one that was already there, waiting in the microbial world, and had figured out how to command it.

The discovery was the culmination of a chain of serendipity and insight stretching back decades. It began with Mojica’s obsession with repeating DNA patterns in salt-loving microbes, a pursuit many considered a scientific dead end. It continued with Barrangou’s applied work in yogurt bacteria, whic